Dengue is one of the most prevalent mosquito-borne diseases in the world, affecting an estimated 390 million people each year, according to models. For the last two decades, efforts to develop safe and effective vaccines to prevent dengue virus (DENV) infections have faced several challenges, mostly related to the complexity of conducting long-term studies to evaluate vaccine efficacy and safety to rule out the risk of vaccine-induced DHS/DSS, particularly in children. At least seven DENV vaccines have undergone different phases of clinical trials; however, only three of them (Dengvaxia^®, TV003, and TAK-003) have showed promising results, and are addressed in detail in this review in terms of their molecular design, efficacy, and immunogenicity. Safety-related challenges during DENV vaccine development are also discussed.

根据模型，登革热是世界上最流行的蚊媒疾病之一，估计每年影响 3.9 亿人。在过去的二十年中，开发安全有效的疫苗以预防登革热病毒 (DENV) 感染的努力面临着若干挑战，主要与进行长期研究以评估疫苗功效和安全性以排除疫苗风险的复杂性有关-诱导的 DHS/DSS，尤其是在儿童中。至少有七种 DENV 疫苗经历了不同阶段的临床试验；然而，其中只有三个（Dengvaxia ^®、TV003 和 TAK-003）已显示出有希望的结果，并在本综述中详细讨论了它们的分子设计、功效和免疫原性。还讨论了 DENV 疫苗开发过程中与安全相关的挑战。